1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • April 2014
  • 390 pages
  • GlobalData
Report ID: 2225873

Summary

Table of Contents

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations.

This Event-Driven Update was published in response to major events that occurred during the first quarter of 2014 that will result in the failure of several premium-priced agents to launch in the US and global markets during the forecast period. These agents include Pfizer’s dacomitinib and Boehringer Ingelheim’s nintedanib in the US, and Roche’s MetMab (onartuzumab) and GSK’s MAGE-A3 immunotherapy in the global markets.

Highlights

Key Questions Answered

- The NSCLC market will become increasingly crowded during the forecast. How will the first and second lines of therapy be impacted by the launch of new therapies?
- How will the failure of dacomitinib and nintedanib to launch in the US affect global market growth? What effect will the failure to launch of MetMab (onartuzumab) and the MAGE-A3 immunotherapy in the nine major markets have on global market dynamics?
- How will the increasing stratification of patient populations by biomarkers affect the treatment landscape?
- The unmet needs of NSCLC patients are relatively high. What unmet needs will be addressed by the launch of new treatment options during the forecast period? What unmet needs will remain?
- How will Alimta, Avastin, Iressa and Tarceva patent expirations affect overall market growth during the forecast?
- How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?

Key Findings

- Launch of emerging pipeline therapies will result in more patients receiving premium-priced drugs in the first and second lines of therapy, and market growth in the US and Japan. However, the US and nine major markets will be negatively affected by the failure of premium-priced agents including dacomitinib, nintedanib, MetMab and MAGE-A3 to launch during the forecast period.
- Despite the launch of remaining premium-priced therapies such as Eli Lilly’s necitumumab and BMS’ nivolumab, the NSCLC market will shrink in the 5EU. This will be primarily due to the reduction in number of new premium-priced agents that will launch as well as the loss of patent protection for most of the major branded therapies as well as increasing cost pressures from European reimbursement authorities.
- The Indian and Chinese markets will continue to be difficult to penetrate. Many emerging pipeline therapies will not launch in these markets, especially expensive biologic therapies. Generic competition, regulatory hurdles and high cost of therapies will be major barriers to growth in these markets.
- BMS’s nivolumab will emerge as the overall market leader in 2022, launching first in the second-line segment in 2015 and expanding into the first-line segment in 2019. Uptake will be driven by the drug’s promising clinical efficacy in both squamous and non-squamous patients and strong safety profile.
- After Iressa and Tarceva lose patent protection in 2019 and 2020, respectively, Boehriger Ingelheim’s Gilotrif (afatinib) will emerge as the leading therapy for EGFR-positive patients. Gilotrif’s market position will be driven by high uptake in the second-line segment.
- Pfizer’s Xalkori will lose ALK-positive patient share to Novartis’ ceritinib (LDK378) in the second-line segment. However, Xalkori will continue to be the patient share leader in the more lucrative first line setting and will maintain the overall sales leadership over LDK378 throughout the forecast.

Scope

- Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized NSCLC therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NSCLC therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising 13 candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Forecast drug sales in the global NSCLC therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The global lung cancer surgery market is segmented based ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...


Download Unlimited Documents from Trusted Public Sources

OTC Industry in the US and Canada

  • May 2017
    14 pages
  • Cancer  

  • United States  

    Canada  

View report >

Cancer Statistics in the US - Forecast

  • May 2017
    9 pages
  • Cancer  

    Pathology  

  • United States  

    Europe  

    United Kingdom  

View report >

Lung Cancer Statistics in the US

  • May 2017
    9 pages
  • Lung Cancer  

  • United States  

View report >

Related Market Segments :

Lung Cancer

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.